Old Web
English
Sign In
Acemap
>
authorDetail
>
Maud Jonnaert
Maud Jonnaert
Novartis
Medicine
non-small cell lung cancer (NSCLC)
Pathology
T790M
Disease
2
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Efficacy of Nazartinib (EGF816) in Adults With EGFR-mutant Non-Small-Cell Lung Carcinoma: A Multicentre, Open-Label, Phase 1 Study
2020
The Lancet Respiratory Medicine
Daniel S.W. Tan
Natasha B. Leighl
Gregory J. Riely
James C-H Yang
Lecia V. Sequist
Juergen Wolf
Takashi Seto
Enriqueta Felip
Santiago Ponce-Aix
Maud Jonnaert
Chun Pan
Eugene Y. Tan
Jinnie Ko
Susan E. Moody
Dong-Wan Kim
Show All
Source
Cite
Save
Citations (19)
Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).
2017
Journal of Clinical Oncology
Daniel Shao-Weng Tan
Dong-Wan Kim
Natasha B. Leighl
Gregory J. Riely
James Chih-Hsin Yang
Juergen Wolf
Takashi Seto
Enriqueta Felip
Santiago Ponce-Aix
Maud Jonnaert
Chun Pan
Sinead Dolan
Jordi Barretina
Susan E. Moody
Lecia V. Sequist
Show All
Source
Cite
Save
Citations (9)
1